Cart
Angiogenesis BTK

BTK

Bruton's tyrosine kinase (abbreviated Btk or BTK), also known as tyrosine-protein kinase BTK, is a tyrosine kinase that is encoded by the BTK gene in humans. BTK plays a crucial role in B cell development.BTK contains five different protein interaction domains. These domains include an amino terminal pleckstrin homology (PH) domain, a proline-rich TEC homology (TH) domain, SRC homology (SH) domains SH2 and SH3, as well as a kinase domain with enzymatic activity.
Cat No. product name
T1835 IbrutinibHOT Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
T1976 RN486 RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).
T2302 CNX-774 CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).
T2472 CGI1746 CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
T2473 PLX4720HOT PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations).
T2603 Spebrutinib Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
T3626 Acalabrutinib Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administ...
T4268 CHMFL-BMX-078 CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
T6078 SaracatinibHOT Saracatinib (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
T6217 LFM-A13 LFM-A13(IC50=2.5 μM),a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases,such as JAK1, JAK2, HCK, E...
T4337 PCI-29732 PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
T4387 evobrutinib Evobrutinib, also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the developme...
T5138 BMS-986142 BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).
T5407 BMS986195 BMS986195 is a potent, covalent inhibitor of Bruton’s tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC50 <1 nM for ...
T7584 zanubrutinib Zanubrutinib is an inhibitor of Bruton tyrosine kinase (BTK).
TQ0039 (±)-Zanubrutinib (±)-Zanubrutinib is a specific, potent and orally available Btk inhibitor.
TQ0230 BTK IN-1 BTK IN-1 (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
TQ0236 Tirabrutinib Tirabrutinib (ONO-4059) is a highly specific and orally bioavailable BTK inhibitor (IC50: 2.2 nM).
TQ0242 Fenebrutinib Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
T3024 Avitinib Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with poten...
T6918 Olmutinib Olmutinib is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity....
T4391 Syk Inhibitor II (hydrochloride) Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ cha...
T12152 N-piperidine Ibrutinib hydrochloride N-piperidine Ibrutinib hydrochloride is an potent inhibitor of BTK (WT BTK and C481S BTK with IC50s of 51.0 and 30.7 nM, respectively).
T12311 Tirabrutinib hydrochloride Tirabrutinib hydrochloride is a selective and novelBTK with IC50 2.2 nm inhibitor.
T12542 PRN1008 PRN1008 is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).
T10240 ACP-5862 ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective...
T14357 Spebrutinib besylate Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).
T14681 BMS-935177 BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk), with an IC50 of 3 nM.
T14692 BMX-IN-1 BMX-IN-1 is a selective and irreversible bone marrow tyrosine kinase on chromosome X (BMX)inhibitor that targets Cys496 in the BMX ATP binding domain with an IC...
T14956 CHMFL-BTK-01 CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.
T15365 G-744 G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthrit...
T11379 GDC-0834  GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse a...
T10629 Btk inhibitor 2 Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).
T16265 Naluzotan Naluzotan is an effective and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM. Naluzotan is used for the treatment of anxiet...
T16441 PCI-33380 PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
T12673L PF-06250112 PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase a...
T16730 Remibrutinib Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC...
T10625 IBT6A IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
T16853 SB-633825 SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, ...
T17098 Tilfrinib Tilfrinib is an effective and selective inhibitor of breast tumor kinase (IC50: 3.15 nM), which displays anti-proliferative activity.
T8636 Ibrutinib deacryloylpiperidine Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
T12317 Orelabrutinib Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).
Ibrutinib HOT
T1835CAS 936563-96-1
Ibrutinib is an irreversible inhibitor of BTK (IC50: 0.5 nM) that selectively blocks B cell activation.
RN486
T1976CAS 1242156-23-5
RN486 is an effective and specific BTK inhibitor (IC50: 4 nM).
CNX-774
T2302CAS 1202759-32-7
CNX-774 is a highly specific, irreversible, and orally active BTK inhibitor (IC50<1 nM).
CGI1746
T2472CAS 910232-84-7
CGI1746 is a potent and highly selective small-molecule Btk inhibitor with IC50 of 1.9 nM.
PLX4720 HOT
T2473CAS 918505-84-7
PLX-4720 is a potent and selective inhibitor of B-Raf (V600E) (IC50: 13 nM), equally potent to c-Raf-1(Y340D and Y341D mutations).
Spebrutinib
T2603CAS 1202757-89-8
Spebrutinib is an orally bioavailable, selective inhibitor of Bruton's agammaglobulinemia tyrosine kinase (BTK), with potential antineoplastic activity.
Acalabrutinib
T3626CAS 1420477-60-6
Acalabrutinib, also known as ACP-196, is an orally available inhibitor of Bruton’s tyrosine kinase (BTK) with potential antineoplastic activity. Upon administ...
CHMFL-BMX-078
T4268CAS 1808288-51-8
CHMFL-BMX-078 is a highly potent and selective type II irreversible BMX kinase inhibitor with an IC50 of 11 nM.
Saracatinib HOT
T6078CAS 379231-04-6
Saracatinib (AZD0530) is an effective Src inhibitor (IC50: 2.7 nM), and effective to Lck, Fyn, Lyn, Blk, Fgr and c-Yes.
LFM-A13
T6217CAS 244240-24-2
LFM-A13(IC50=2.5 μM),a specific Bruton's tyrosine kinase (BTK), is more than 100-fold specificity than other protein kinases,such as JAK1, JAK2, HCK, E...
PCI-29732
T4337CAS 330786-25-9
PCI 29732 is a selective and irreversible Btk inhibitor with IC50 of 8.2 nM in a FRET based biochemical enzymology assay.
evobrutinib
T4387CAS 1415823-73-2
Evobrutinib, also known as M-2951 and MSC-2364447C, is a highly selective inhibitor of the Bruton’s tyrosine kinase (BTK), which is important in the developme...
BMS-986142
T5138CAS 1643368-58-4
BMS-986142 is a potent and highly selective reversible BTK inhibitor (IC50: 0.5 nM).
BMS986195
T5407CAS 1912445-55-6
BMS986195 is a potent, covalent inhibitor of Bruton’s tyrosine kinase (BTK), >5,000-fold selective over all kinases outside of the Tec family (IC50 <1 nM for ...
zanubrutinib
T7584CAS 1691249-45-2
Zanubrutinib is an inhibitor of Bruton tyrosine kinase (BTK).
(±)-Zanubrutinib
TQ0039CAS 1633350-06-7
(±)-Zanubrutinib is a specific, potent and orally available Btk inhibitor.
BTK IN-1
TQ0230CAS 1270014-40-8
BTK IN-1 (SNS062 analog) is an effective BTK inhibitor (IC50: <100 nM).
Tirabrutinib
TQ0236CAS 1351636-18-4
Tirabrutinib (ONO-4059) is a highly specific and orally bioavailable BTK inhibitor (IC50: 2.2 nM).
Fenebrutinib
TQ0242CAS 1434048-34-6
Fenebrutinib (GDC-0853) is a selective and noncovalent Btk inhibitor (Ki: 0.91 nM).
Avitinib
T3024CAS 1557267-42-1
Avitinib, also known as AC0010 or AC0010MA, is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with poten...
Olmutinib
T6918CAS 1353550-13-6
Olmutinib is an orally available small molecule, a mutant-selective inhibitor of epidermal growth factor receptor (EGFR) with potential antineoplastic activity....
Syk Inhibitor II (hydrochloride)
T4391CAS 227449-73-2
Spleen tyrosine kinase (Syk) is a non-receptor tyrosine kinase that, upon phosphorylation, binds to immunoreceptor tyrosine-based activation motifs of FcRγ cha...
N-piperidine Ibrutinib hydrochloride
T12152CAS 2231747-18-3
N-piperidine Ibrutinib hydrochloride is an potent inhibitor of BTK (WT BTK and C481S BTK with IC50s of 51.0 and 30.7 nM, respectively).
Tirabrutinib hydrochloride
T12311CAS 1439901-97-9
Tirabrutinib hydrochloride is a selective and novelBTK with IC50 2.2 nm inhibitor.
PRN1008
T12542CAS 1575596-29-0
PRN1008 is a reversible covalent, selective and oral active inhibitor of Bruton’s Tyrosine Kinase (BTK)(IC50 of 1.3 nM).
ACP-5862
T10240CAS 2230757-47-6
ACP-5862 is a major active and pyrrolidine ring-opened metabolite of Acalabrutinib (IC50: 5.0 nM for BTK). Acalabrutinib is an irreversible and highly selective...
Spebrutinib besylate
T14357CAS 1360053-81-1
Spebrutinib besylate (AVL-292 benzenesulfonate; CC-292 besylate) is a Btk kinase activity inhibitor (IC50<0.5 nM, Kinact/Ki=7.69×104 M-1s-1s).
BMS-935177
T14681CAS 1231889-53-4
BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk), with an IC50 of 3 nM.
BMX-IN-1
T14692CAS 1431525-23-3
BMX-IN-1 is a selective and irreversible bone marrow tyrosine kinase on chromosome X (BMX)inhibitor that targets Cys496 in the BMX ATP binding domain with an IC...
CHMFL-BTK-01
T14956CAS 2095280-64-9
CHMFL-BTK-01 is an irreversible inhibitor of BTK (IC50: 7 nM) and also potently inhibits BTK Y223 auto-phosphorylation.
G-744
T15365CAS 1346669-54-2
G-744 is a selective and orally active inhibitor of Btk (IC50: 2 nM). G-744 is well-tolerated, metabolically stable. It also has an efficacious to treat arthrit...
GDC-0834
T11379CAS 1133432-49-1
 GDC-0834 inhibits BTK with an in vitro IC50 of 5.9 and 6.4 nM in biochemical and cellular assays, respectively, and in vivo IC50 of 1.1 and 5.6 μM in mouse a...
Btk inhibitor 2
T10629CAS 1558036-85-3
Btk inhibitor 2 is a BTK inhibitor extracted from patent US 20170224688 A1 (BGB-3111 analog).
Naluzotan
T16265CAS 740873-06-7
Naluzotan is an effective and selective amidosulfonamide 5-HT1A agonist with IC50 and Ki of appr 20 nM and 5.1 nM. Naluzotan is used for the treatment of anxiet...
PCI-33380
T16441CAS 1022899-36-0
PCI-33380 is an irreversible inhibitor of Bruton's Tyrosine Kinase.
PF-06250112
T12673LCAS 1609465-89-5
PF-06250112 is an effective and highly selective BTK inhibitor (IC50: 0.5 nM. PF-06250112 displays an inhibitory effect toward BMX nonreceptor tyrosine kinase a...
Remibrutinib
T16730CAS 1787294-07-8
Remibrutinib inhibits BTK activity with an IC50 value of 0.023 μM in blood. Remibrutinib is an effective and orally active Bruton tyrosine kinase inhibitor (IC...
IBT6A
T10625CAS 1022150-12-4
IBT6A is an impurity of Ibrutinib. Ibrutinib is a Btk inhibitor (IC50: 0.5 nM). IBT6A can be used in the synthesis of IBT6A Ibrutinib dimer and IBT6A adduct.
SB-633825
T16853CAS 956613-01-7
SB-633825 can inhibit cancer cell growth and angiogenesis. SB-633825 is an effective and ATP-competitive inhibitor of TIE2, LOK, and BRK (IC50s: 3.5 nM, 66 nM, ...
Tilfrinib
T17098CAS 1600515-49-8
Tilfrinib is an effective and selective inhibitor of breast tumor kinase (IC50: 3.15 nM), which displays anti-proliferative activity.
Ibrutinib deacryloylpiperidine
T8636CAS 330786-24-8
Ibrutinib deacryloylpiperidine is a highly selective Bruton’s tyrosine kinase (BTK) irreversible inhibitor with an IC50 of 0.5 nM.
Orelabrutinib
T12317CAS 1655504-04-3
Orelabrutinib is an orally active and irreversible inhibitor of Bruton's tyrosine kinase (BTK).